Unicycive Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
UNCY$3.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2024
Balance Sheets
(in thousands, except for share and per share amounts)
| As of | As of | |
|---|---|---|
| December 31, | December 31, | |
| 2023 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash | $9,701 | $26,142 |
| Prepaid expenses and other current assets | 3,698 | 4,806 |
| Total current assets | 13,399 | 30,948 |
| Right of use asset, net | 766 | 645 |
| Property, plant and equipment, net | 26 | 75 |
| Total assets | $14,191 | $31,668 |
| Liabilities and stockholders’( deficit) equity | ||
| Current liabilities: | ||
| Accounts payable | $839 | $1,058 |
| Accrued liabilities | 3,234 | 3,562 |
| Warrant liability | 13,134 | 18,936 |
| Operating lease liability – current | 327 | 564 |
| Total current liabilities | 17,534 | 24,120 |
| Operating lease liability – long term | 466 | 117 |
| Total liabilities | 18,000 | 24,237 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ (deficit) equity: | ||
| Series A-2 Prime preferred stock, $0.001 par value per share – 43,649 Series A-2 shares authorized at December 31, 2023 and 21,388.01 Series A-2 Prime shares authorized at December 31, 2024; 43,649 Series A-2 shares outstanding at December 31, 2023 and 6,150.21 Series A-2 Prime shares outstanding at December 31, 2024 | - | - |
| Series B-2 preferred stock, $0.001 par value per share – zero and 7,882 shares authorized at December 31, 2023 and December 31, 2024, respectively; zero and 3,000 shares outstanding at December 31, 2023 and December 31, 2024, respectively | ||
| Preferred stock: $0.001 par value per share—9,926,161 and 9,846,891 shares authorized at December 31, 2023 and December 31, 2024, respectively; zero shares issued and outstanding at December 31, 2023 and December 31, 2024 | - | - |
| Common stock, $0.001 par value per share – 200,000,000 and 400,000,000 shares authorized at December 31, 2023 and 2024, respectively; 34,756,049 shares issued and outstanding at December 31, 2023 and 113,842,364 issued and outstanding at December 31, 2024 | 35 | 114 |
| Additional paid-in capital | 60,697 | 108,587 |
| Accumulated deficit | (64,541) | (101,270) |
| Total stockholders’(deficit) equity | (3,809) | 7,431 |
| Total liabilities and stockholders’ (deficit) equity | $14,191 | $31,668 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.